New Chemotherapy-Free Leukemia Trial Results
Adults diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia achieved superior disease control without traditional chemotherapy, according to phase 3 trial results published in the New England Journal of Medicine doi: 10.1056/NEJMoa2606208
and reported by The Tyrrhenian Sea.
Researchers at the Sapienza University of Rome and the Fondazione Gimema Franco Mandelli ETS tested a combination therapy involving the third-generation tyrosine kinase inhibitor ponatinib and the bispecific antibody blinatumomab. The findings mark a major shift for a blood cancer historically linked to poor prognoses, as noted by the Republic, opening the door to a new standard of care for adult Philadelphia-positive acute lymphoblastic leukemia.
Two Decades of Italian Clinical Research
This breakthrough builds on a clinical research path that began in Italy in the year 2000 with the Gimema Lal0201 protocol, which first explored using targeted inhibitors without upfront chemotherapy.
Over the next twenty years, the Gimema group progressively evaluated first-, second-, and third-generation tyrosine kinase inhibitors to reduce reliance on conventional cytotoxic drugs, as detailed by World Health. Starting from the early 2000s, the introduction of tyrosine kinase inhibitors improved therapeutic results and led to more targeted, less intensive treatment strategies.
The independent foundation coordinates a national network of roughly 140 hematology centers and 61 biological laboratories across Italy, allowing researchers to conduct complex molecular analyses. reported that Gimema’s scientific coordinator Alfonso Piciocchi emphasized the unique value of proving a chemotherapy-free regimen’s superiority within a randomized trial setting. The Data Center, based in Rome, is the operational hub that coordinates all the Foundation’s research activities and manages numerous international collaborations.
Gimema All2820 trial enrolled 236 adult patients
Between September 2021 and January 2025, the Gimema All2820 trial enrolled 236 newly diagnosed adult patients ranging in age from 24 to 82 years old. Among them, 158 participants received the experimental regimen of ponatinib followed by two to five intravenous cycles of blinatumomab, while 78 participants received standard care consisting of the inhibitor imatinib paired with traditional chemotherapy.
The trial’s primary endpoint measured event-free survival, tracking overall survival, hematological response, molecular disease persistence, and relapse rates. Particular focus was placed on molecular response to detect minimal residual disease below the threshold of conventional examinations, according to trial documentation.
Experimental arm showed higher event-free survival and remission rates
At two years post-treatment, 86% of patients in the experimental arm remained free of events, compared to 67% in the standard therapy group. Following the initial induction phase, 94% of patients in the experimental group reached complete hematological remission, versus 79% in the standard cohort, according to World Health.
Deeper molecular responses were achieved by 71% of the chemotherapy-free group, contrasted with 49% of the traditional treatment group. Furthermore, overall survival at two years reached 90% for the experimental arm and 85% for the standard arm, with cumulative relapse probabilities standing at 5% and 13% respectively, while severe adverse events affected 34% of the experimental group compared to 47% of controls, as reported by the Republic.
Longer observation is required to establish long-term durability
Foundation president Marco Vignetti noted that independent clinical research directly addresses patient needs despite operating with fewer resources than the commercial pharmaceutical industry, according to HANDLE. Trial investigators emphasize that median follow-up currently sits at approximately two years, requiring longer observation to establish long-term durability, and note that specialized hematological care remains necessary because chemotherapy-free regimens still carry distinct side effects, as highlighted by World Health.
What genetic mutation causes Philadelphia-positive acute lymphoblastic leukemia?
What genetic mutation causes Philadelphia-positive acute lymphoblastic leukemia?
The disease stems from a chromosomal translocation where genetic material is exchanged between two chromosomes, fusing the BCR and ABL1 genes. This creates an abnormal BCR-ABL1 fusion protein whose unchecked enzymatic activity drives rapid, uncontrolled cell proliferation, as outlined in study background data reported by the Republic.
This genetic alteration in the so-called Philadelphia chromosome is extremely common in chronic myeloid leukemia, but is also found in about a third of acute lymphoblastic leukemia cases.
How many treatment cycles were administered in the trial?
Following initial induction therapy with the third-generation tyrosine kinase inhibitor ponatinib, patients in the experimental arm received between two and five intravenous cycles of the bispecific antibody blinatumomab during the consolidation phase, according to World Health.
What institutions promoted and coordinated the trial?
The phase 3 Gimema All2820 trial was promoted by the Fondazione Gimema Franco Mandelli ETS and coordinated by hematology professors Sabina Chiaretti and Robin Foà from the Sapienza University of Rome, as reported by The Tyrrhenian Sea.
Keep reading